Loading…

Daewoong003090.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Pharmaceuticals: Major
Momentum strong 65
Mkt cap
$495M
US dollars, full cap
Free float
62%
of shares outstanding
$/day
$783,843
20-day average traded
Fwd P/E
4.1×
forward earnings
ROIC−WACC
+1.3 pp
WACC 5.0%
Hurdle
n/a
no reverse DCF
Next earnings
125 days
23 Mar 2027
Close · KRW₩15,660
1D-4.0%
1W+0.3%
1M+0.3%
3M-13.5%
6M-27.5%
YTD-29.0%
1Y-29.5%
ATR %4.3%
52w lowhigh48.8% off high

What Daewoong does

Employees: 413

Daewoong at a glance

Size Daewoong (003090.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $495M, the 347th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩15,660 on 18 Nov 2026.

Performance Over six months the shares fell 27.5%, against -12.8% for the median peer and -37.2% for the South Korea market (cap-weighted) — 4th lowest of 21 in its peer set.

Growth Revenue grew 5.7% over the last twelve months (peer median +13.0%); the operating margin is 11.4% (peer median 10.0%).

Valuation It trades at 4.1× forward earnings against a peer median of 18.2× (cheapest of 6).

Capital Return on invested capital runs 1.3 points above its cost of capital (5.0% WACC).

Next results Next results expected around 23 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 88003090.KS 74
Six months, rebased to 100: Daewoong against the median of its 20 peers (local-currency closes).

Daewoong financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩2.17T₩2.07T₩1.94T₩1.82T₩1.70T
Revenue growth—+7%+7%+7%—
Gross profit₩1.14T₩1.09T₩1.04T₩925B₩893B
EBITDA₩340B₩323B₩338B₩248B₩255B
Net income₩171B₩175B₩57.9B₩153B₩103B
Free cash flow-₩62.1B-₩37.2B-₩115B₩19.2B₩40.5B
Capital expenditure₩344B₩348B₩336B₩229B₩118B
Total debt₩1.00T₩878B₩718B₩477B₩495B

Quarterly statements and history in the cockpit →

Daewoong competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%0%+20%600513TKNO600222AARTIDRUGS0021071666GYRE603207301277GUJTHEMINDPEGTXRGNXHNSA600624SMSPHARMA003090.KS6-month return →1-month return →
Up and to the right = strong over both horizons. Daewoong is the large dot.

Fundamentals: revenue growth against valuation

-10%0%+10%+20%20×40×AARTIDRUGS1666003020EGTXSMSPHARMA003090.KSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Daewoong is the large dot.

Daewoong competitors and peer comparison

How Daewoong compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Daewoong against its 20 peers (data as of 18 Nov 2026)
Measure003090.KSPeer medianRank in peer set
1-month return+0.3%-2.1%9th highest of 21
6-month return-27.5%-12.8%4th lowest of 21
Distance from 52-week high-48.8%-34.8%5th lowest of 21
Revenue growth (TTM)+5.7%+13.0%8th lowest of 20
Operating margin11.4%10.0%9th highest of 20
Forward P/E4.1×18.2×cheapest of 6
ROIC minus cost of capital+1.3 pp-2.7 pp7th highest of 18
EV / EBITDA5.8×19.2×2nd cheapest of 5
Net debt / EBITDA2.1×1.6×most indebted of 5

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Daewoong 003090.KSSouth Korea$495M-28%+6%11%4.1×n/an/a
Jiangsu Lianhuan Pharmaceutical 600513.SSChina$496M-41%+14%0%n/an/an/a
Alpha Teknova TKNOUnited States$496M+113%+15%-32%n/an/an/a
Henan Taloph Pharmaceutical Stock 600222.SSChina$497M-21%-5%7%n/a16.7%+4.4%
Aarti Drugs AARTIDRUGS.NSIndia$494M+34%+15%11%21.3×22.1%+3.5%
Shandong Wohua Pharmaceutical 002107.SZChina$493M-20%-4%18%n/a5.9%-4.1%
Tong Ren Tang Technologies 1666.HKHong Kong$491M-19%-14%12%7.3×-17.2%+6.3%
Gyre Therapeutics GYREUnited States$500M-28%+14%-18%n/an/an/a
Shanghai Xiao Fang Pharmaceutical 603207.SSChina$503M-17%+10%39%n/a-5.4%+7.6%
Newland Pharmaceutical 301277.SZChina$488M-22%+9%11%n/a8.9%+9.1%
Nanjing Hicin Pharmaceutical 300584.SZChina$487M-29%+32%17%n/a3.3%-1.1%
Hefei Lifeon Pharmaceutical 003020.SZChina$486M-21%-1%10%18.2×n/an/a
Gujarat Themis Biosyn GUJTHEM.NSIndia$505M+2%+18%39%n/an/an/a
Indaptus Therapeutics INDPUnited States$505M+147%n/an/an/an/an/a
Egetis Therapeutics EGTX.STSweden$509M+76%+27%-645%15.1×n/an/a
Shanghai MicuRx Pharmaceutical 688373.SSChina$481M-8%+23%-61%n/an/an/a
REGENXBIO RGNXUnited States$480M+22%-5%-120%n/an/an/a
Hansa Biopharma HNSA.STSweden$479M+39%+69%-190%n/a-4.7%+105.3%
Xizang Weixinkang Pharmaceutical 603676.SSChina$513M-22%-8%16%n/a-6.1%+9.6%
Shanghai Fudan Forward S&T 600624.SSChina$478M0%-14%-34%n/an/an/a
SMS Pharmaceuticals SMSPHARMA.NSIndia$477M+16%+13%16%42.2×n/an/a

Questions

Which companies are Daewoong's closest peers?
The cockpit's peer set: Jiangsu Lianhuan Pharmaceutical (600513.SS), Alpha Teknova (TKNO), Henan Taloph Pharmaceutical Stock (600222.SS), Aarti Drugs (AARTIDRUGS.NS), Shandong Wohua Pharmaceutical (002107.SZ), Tong Ren Tang Technologies (1666.HK), Gyre Therapeutics (GYRE), Shanghai Xiao Fang Pharmaceutical (603207.SS).
Is Daewoong expensive compared with its peers?
On forward p/e it trades at 4.1× against a peer median of 18.2×, cheapest of 6 in its peer set.
How has Daewoong stock performed?
Over six months to 18 Nov 2026 the shares returned -27.5% against -12.8% for the median peer; over one year -29.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.